059sek
1,0 %
Date:2024-11-22Time:13:32:31Latest report:Q2-2024List:Small CapTicker:IMMNOV
Market Cap:98 msekEnterprise Value:70 msekNet Sales:0,88 msekEarnings:-116,1 msekEmployees:0ISIN:SE0006091997

Ratios

10-year key figure history for Immunovia turnover, profit, dividend, equity, PE and PB.

Pre
Pre

Stockprice

Price movement for Immunovia with index and moving average MA50 and MA200.

Stockprice:0,59
MA50:0,67
MA200:1,30
Price/MA200:-55,5 %
RSI (14):43,4
Price/MA50:-13,1 %

Description

Immunovia AB molecular diagnostic company. It develops and commercializes diagnostic tools for complex forms of cancer and autoimmune diseases. Its technology platform IMMray (TM), is based on antibody microarray analysis. The company is currently developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer.

Medical Equipment